iRhythm Holdings (IRTC) has drawn fresh attention after recent share price moves, with the stock showing a 4.6% decline over the past day and a 13.4% slide over the past month.
See our latest analysis for iRhythm Holdings.
The recent 1 day share price return of 4.6% decline adds to a 30 day share price return of 13.4% decline and a year to date share price return of 23.7% decline. At the same time, the 1 year total shareholder return of 22.6% shows a very different long term picture, suggesting momentum has faded recently as investors reassess both growth potential and risk around the current US$133.75 share price.
If this shift in sentiment around iRhythm has you looking wider across healthcare technology, it could be worth scanning our list of 28 healthcare AI stocks as another source of ideas.
With iRhythm trading at US$133.75 and indicators like its intrinsic discount and gap to analyst price targets in view, investors may be asking whether the recent weakness represents an opportunity or whether the market is already pricing in future growth.
Most Popular Narrative: 37.2% Undervalued
With iRhythm closing at $133.75 against a narrative fair value of $212.87, the current share price sits well below that widely followed estimate, which is built using an 8.04% discount rate.
Investment in the Zio ecosystem, including next-generation patches, enhanced form factors, and AI-powered analytics (such as the Lucem Health partnership), is improving product differentiation, diagnostic yield, and workflow efficiency, likely leading to higher gross margins and operating leverage as software and data become a larger component of the business.
Want to see what kind of revenue runway and margin shift would need to line up to support that higher value and future earnings profile? The full narrative lays out detailed growth, profitability and valuation assumptions that go well beyond headline guidance.
Result: Fair Value of $212.87 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, it is worth keeping in mind that ongoing regulatory inquiries and reliance on key channel partners could still affect growth expectations and put pressure on margins.
Find out about the key risks to this iRhythm Holdings narrative.
Another Lens On Value: Revenue Multiple Sends A Different Signal
While the narrative fair value and DCF style work suggest iRhythm looks underpriced, the current P/S of 5.8x tells a different story. It sits well above the US Medical Equipment industry at 2.9x, peers at 5x, and a fair ratio of 4.1x, which points to valuation risk if sentiment cools. Which signal do you trust more when prices move quickly?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
If the mix of signals here leaves you undecided, it makes sense to move quickly, review the underlying figures yourself and weigh the upside. To round out your view, take a look at the 3 key rewards that investors are currently focused on.
Looking for more investment ideas?
If this update has sharpened your focus on quality, do not stop here. The next decision you skip could be the one that reshapes your portfolio.
- Target potential mispricings by scanning our 49 high quality undervalued stocks that combine strong fundamentals with prices the market may be overlooking.
- Strengthen your income stream by reviewing 13 dividend fortresses that offer higher yields with a focus on resilience.
- Prioritize resilience and capital preservation by checking 76 resilient stocks with low risk scores that score well on financial strength and risk controls.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com